Rowan Regional Medical Center

Summary

Rowan Regional Medical Center is a medical facility located in Salisbury, North Carolina. This center is recognized for care of Breast Cancer, Breast cancer, Lung Cancer, Esophageal cancer, Esophageal Cancer and other specialties. Rowan Regional Medical Center is involved with conducting 18 clinical trials across 56 conditions. There are 5 research doctors associated with this hospital, such as Alan Skarbnik, MD, Kimberly S. Strickland, Nasfat Shehadeh, M.D., and Kevin S. Roof.

Top PIs

Clinical Trials running at Rowan Regional Medical Center

Breast Cancer

Testicular cancer

Breast cancer

Ovarian Carcinoma

Ovarian Tumors

Testicular Carcinoma

Ovarian Choriocarcinoma

Small Cell Lung Cancer

Lung Cancer

Testicular Choriocarcinoma

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.

Recruiting

2 awards

Phase 3

19 criteria

HER2-Targeted Therapy

for Breast Cancer

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherapy with trastuzumab. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to a receptor protein called HER2. HER2 is found on some cancer cells. When trastuzumab or pertuzumab attach to HER2, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving 6 months of HER2-targeted therapy may work better than giving 12 months for the treatment of HER2+ breast cancer in patients that had a pCR after neoadjuvant chemotherapy with trastuzumab.

Recruiting

2 awards

Phase 3

5 criteria

Hormone Therapy with or without Radiation

for Breast Cancer

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.

Recruiting

2 awards

Phase 3

13 criteria